Part D Cost Sharing Cap Offered In Draft US House Bill, But Not How To Pay For It
Executive Summary
Biopharma manufacturers might not like the cost offsets that would cover the out-of-pocket maximum for patients in Medicare's drug program; committees seek comment on range of issues.